ATECTURA BREEZHALER CAPSULE

Pajjiż: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

INDACATEROL (INDACATEROL ACETATE); MOMETASONE FUROATE

Disponibbli minn:

NOVARTIS PHARMACEUTICALS CANADA INC

Kodiċi ATC:

R03AK14

INN (Isem Internazzjonali):

INDACATEROL AND MOMETASONE

Dożaġġ:

150MCG; 80MCG

Għamla farmaċewtika:

CAPSULE

Kompożizzjoni:

INDACATEROL (INDACATEROL ACETATE) 150MCG; MOMETASONE FUROATE 80MCG

Rotta amministrattiva:

INHALATION

Unitajiet fil-pakkett:

15G/50G

Tip ta 'preskrizzjoni:

Prescription

Żona terapewtika:

ADRENALS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0262235001; AHFS:

L-istatus ta 'awtorizzazzjoni:

APPROVED

Data ta 'l-awtorizzazzjoni:

2020-05-06

Karatteristiċi tal-prodott

_ATECTURA_
_®_
_ BREEZHALER_
_®_
_ Product Monograph _
_Page 1 of 39_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
ATECTURA® BREEZHALER®
Indacaterol (as acetate)/mometasone furoate inhalation powder hard
capsules
150 mcg/80 mcg
150 mcg/160 mcg
150 mcg/320 mcg
ATECTURA BREEZHALER capsules to be used only with the supplied
ATECTURA BREEZHALER inhalation
device
Bronchodilator (Long-Acting Beta
2
-Adrenergic Agonist (LABA)) and Inhaled Corticosteroid (ICS)
Combination for Oral Inhalation
Novartis Pharmaceuticals Canada Inc.
385 Bouchard Blvd.
Dorval, Quebec
H9S 1A9
Date of Initial Authorization:
May 5, 2020
Date of Revision:
Nov 12, 2021
Submission Control Number: 246914
ATECTURA and BREEZHALER are registered trademarks.
_ _
_ATECTURA_
_®_
_ BREEZHALER_
_®_
_ Product Monograph _
_Page 2 of 39_
RECENT MAJOR LABEL CHANGES
7 Warnings and Precautions, Endocrine and Metabolism
11/2021
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
RECENT MAJOR LABEL CHANGES
...........................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
...................................................................................................................
4
1.2
Geriatrics
...................................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
4
DOSAGE AND ADMINISTRATION
.................................................................................
4
4.1
Dosing Considerations
..........